Orlisis 120 Capsule contains Orlistat 120 mg, a potent lipase inhibitor indicated for the management of obesity. It acts by selectively inhibiting gastric and pancreatic lipases, enzymes responsible for the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. By preventing the breakdown and subsequent absorption of approximately 30% of ingested fat, Orlisis 120 facilitates weight reduction in conjunction with a reduced-calorie diet. This medication is prescribed for adults with a body mass index (BMI) of 30 kg/m² or greater, or those with a BMI of 27 kg/m² or above who present with obesity-related risk factors such as hypertension, type 2 diabetes, or dyslipidemia. Clinical studies have demonstrated that Orlistat, when used alongside lifestyle modifications, significantly improves weight loss outcomes and contributes to the improvement of cardiovascular risk markers. The recommended dosage is one capsule taken three times daily with each main meal containing fat. Common adverse effects include gastrointestinal symptoms such as oily spotting, flatulence with discharge, and fecal urgency, which are generally mild and related to fat intake. Patients should adhere to a nutritionally balanced, reduced-fat diet to minimize side effects and optimize therapeutic benefits. Orlisis 120 should be used under medical supervision with periodic monitoring of liver function and fat-soluble vitamin levels.